Immune checkpoint blockade (ICB) has transformed the therapeutic paradigm of several cancers and is now FDA‐approved as monotherapy, combined anti‐PD‐(L)1/CTLA‐4 therapy, or in combination with chemotherapy for treatment of several tumour types including melanoma, lung cancer, urothelial cancer and head and neck cancer. The gene discussed is CD274; the disease is neoplasm.